For instance, capturing ALK [55] or ROS1 [56] fusion breakpoints in EV-DNA from lung cancer patients allow identification of candidates for ALK/ROS1 inhibitors even when tissue biopsy is infeasible. Here, ALK is linked to lung carcinoma.